A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC ... with blockade of EGFR, both mutations that are seen in NSCLC tumours.

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC ... including EGFR inhibitors. Teliso-V is currently ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new ...

Taiho Pharmaceutical and Taiho Oncology reported that a Phase 1/2 study of the drug zipalertinib met its primary endpoint of overall response rate in a study of EGFR lung cancer patients. The drug was ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer. Lung cancer is the commonest cancer ...